Article Text

PDF

PO-0495 Intravenous Ibuprofen (ibu) Vs Continuous Indomethacin-infusion (ind-inf) For Symptomatic Patent Ductus Arteriosus (pda) Treatment In Newborns
  1. N Storring,
  2. P Amess,
  3. N Aiton,
  4. R Bomont,
  5. H Rabe,
  6. JR Fernandez Alvarez
  1. Neonatology, Brighton and Sussex University Hospitals NHS Trust, Brighton, UK

Abstract

Background IBU is equivalent to IND for PDA-treatment. IBU reduces less cerebral, mesenteric and renal perfusion and platelet function. IND-INF seems to have similar effects on circulation, but the clinical efficacy of this approach is unclear.

Aim To compare the efficacy and safety of PDA-treatment using 36-hour IND-INF vs IBU in preterm infants.

Methods Retrospective matched-pair cohort-analysis of infants <28GA from a tertiary centre (2012–2014). Infants matched for: Chorioamnionitis, antenatal steroids, vaginal delivery, GA, birthweight, gender, surfactant-administration, mechanical-ventilation, oxygen-requirement (FiO2), PDA-width (wPDA), inotropes, fluid-intake, plasma sodium (SOD), plasma-creatinine (CREA), platelet count (THROM), cerebral resistance-index (cRI) and treatment-age. Outcome measures: wPDA, number of closed (cPDA), restrictive (rPDA), re-opened (rePDA) PDA; FiO2, BPD, SOD, CREA, intestinal perforation (IP), necrotising enterocolitis (NEC), THROM, cRI, IVH, ROP, mortality. Data-presentation: Median (interquartile range) or ratio (n/N). Data-analysis: Fisher’s-Exact-/Mann-Whitney-Test (p < 0.05).

Results 16 newborns (8 IND-INF/8 IBU) recruited. Baseline-characteristics (GA 26 [25–27] vs 26 [25–26], p = 0.65; birthweight 842 g [597–925] vs 777 g [730–801], p = 0.88; rest not displayed) and outcomes were not significantly different:

Abstract PO-0495 Table 1

Conclusion IND-INF appears to be as safe as IBU whilst maintaining the same efficacy for treatment of symptomatic PDA in newborns <28 GA.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.